Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) generates frequent news across neuroscience and oncology, reflecting its focus on serious diseases such as sleep disorders, rare epilepsies, HER2-driven cancers and aggressive brain tumors. This news page aggregates company press releases and third-party coverage so readers can follow how Jazz’s clinical programs, marketed medicines and corporate actions evolve over time.
Visitors can expect updates on clinical trial results and data presentations for products like Epidiolex/Epidyolex (cannabidiol), Xywav (low-sodium oxybate), Ziihera (zanidatamab-hrii) and Modeyso (dordaviprone). Jazz regularly announces new Phase 3 and Phase 4 findings, real-world evidence analyses, and translational research presented at major meetings such as the European Epilepsy Congress, American Epilepsy Society Annual Meeting, World Sleep Congress, ASCO Gastrointestinal Cancers Symposium and the Society for Neuro-Oncology Annual Meeting.
News items also cover regulatory milestones, such as indications granted by the U.S. Food and Drug Administration and other health authorities, as well as designations like Breakthrough Therapy, Fast Track and Orphan Drug status for certain oncology assets. Corporate announcements may include executive appointments, board changes, investor webcasts, participation in healthcare conferences and legal or settlement updates disclosed in tandem with SEC filings.
For investors, clinicians and patients researching JAZZ, this page offers a centralized view of how Jazz Pharmaceuticals communicates progress in sleep medicine, epilepsy, oncology and neuro-oncology. By reviewing the news feed over time, readers can see how key programs advance from early data readouts through larger trials, regulatory interactions and post-approval evidence generation.
Jazz Pharmaceuticals announced the presentation of 10 abstracts at Virtual SLEEP 2020, the annual meeting of the Associated Professional Sleep Societies, from August 28-30. These presentations showcase significant advancements in sleep medicine, particularly research related to Xywav™ (JZP-258), aimed at treating narcolepsy. Key highlights include studies on health-related quality of life and dose titration in narcolepsy patients. The event features ongoing research on innovative therapies for chronic sleep disorders, emphasizing Jazz's commitment to improving patient outcomes.
Jazz Pharmaceuticals announced its Q2 2020 financial results, showcasing a total revenue increase of 5% year-over-year to $562.4 million. Key highlights included a net income of $114.8 million, though down from $261.9 million in Q2 2019. The company reported strong sales in its neuroscience segment, with Xyrem sales rising 8% to $446.8 million. The FDA approval of Xywav and successful launch of Zepzelca within six months were pivotal moments. Additionally, Jazz updated its financial guidance, projecting 2020 revenues between $2.225 billion and $2.325 billion, marking an increase from earlier estimates.
Jazz Pharmaceuticals announced the FDA approval of Xywav on July 21, 2020, for treating cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy aged 7 and older. Xywav features a unique formulation with 92% less sodium than standard sodium oxybate, which may help patients comply with daily sodium intake recommendations. The approval is based on a Phase 3 clinical study involving 201 patients, showing significant efficacy in reducing cataplexy attacks and improving sleepiness scores. Xywav will launch by the end of the year following implementation of a Risk Evaluation and Mitigation Strategy (REMS).
Jazz Pharmaceuticals announces FDA approval of Zepzelca (lurbinectedin) for treating metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy failure. The accelerated approval is based on a clinical study demonstrating a 35% overall response rate (ORR) and a median response duration of 5.3 months. Zepzelca will be available in the U.S. by early July 2020, following a licensing agreement with PharmaMar, effective January 2020. The treatment offers a new option for patients with limited choices, although continued approval depends on further trials confirming its clinical benefits.